Nevertheless, we and others (Irvine et al., 2012; Németh et al., 2016; Ruppert et al., 2019) demonstrated that chronic enhancement of cGMP signaling by pharmacological activation of sGC might be a novel therapeutic approach to prevent pathologic myocardial hypertrophy. The gene discussed is SGCB; the disease is cardiac hypertrophy.